ERBB2 and neoplasm: In both OE19 and NCI N87 HER2+ tumour xenografts, this regimen resulted in significantly prolonged tumour regression (Fig. 5d), increased doubling time (Table 1, Supplementary Table 5), while mice maintained their weight (Supplementary Fig. 10).